Home › Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis clinical trials recruiting in the U.S.
27 studies for Idiopathic Pulmonary Fibrosis are recruiting participants at sites across the United States.
Cities with the most studies
- Birmingham, AL9 studies
- New York City, NY8 studies
- Los Angeles, CA7 studies
- Kansas City, KS7 studies
- Philadelphia, PA7 studies
- Durham, NC6 studies
- Chicago, IL6 studies
- Aurora, CO6 studies
- Atlanta, GA5 studies
- Charleston, SC5 studies
- Dallas, TX5 studies
- Nashville, TN5 studies
- Detroit, MI5 studies
- Houston, TX5 studies
- Baltimore, MD4 studies
- Oklahoma City, OK4 studies
- Ann Arbor, MI4 studies
- Salt Lake City, UT4 studies
- Newport Beach, CA4 studies
- Winston-Salem, NC4 studies
- El Paso, TX4 studies
- Denver, CO3 studies
- Boston, MA3 studies
- Pittsburgh, PA3 studies
- Champaign, IL3 studies
- Greensboro, NC3 studies
- Denison, TX3 studies
- Charlottesville, VA3 studies
- Orlando, FL3 studies
- Richmond, VA3 studies
- Arlington, VA3 studies
- New Haven, CT3 studies
- Mountain View, CA3 studies
- Cincinnati, OH3 studies
By state
- Alabama9 studies
- Arizona5 studies
- California12 studies
- Colorado9 studies
- Connecticut4 studies
- Florida10 studies
- Georgia5 studies
- Illinois8 studies
- Kansas7 studies
- Kentucky3 studies
- Louisiana4 studies
- Maryland4 studies
- Massachusetts4 studies
- Michigan7 studies
- Missouri6 studies
- New York8 studies
- North Carolina10 studies
- Ohio5 studies
- Oklahoma4 studies
- Oregon3 studies
- Pennsylvania12 studies
- South Carolina8 studies
- Tennessee6 studies
- Texas11 studies
- Utah5 studies
- Virginia8 studies
- Wisconsin3 studies
Recently updated studies
An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06951217A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.
RecruitingPhase 2
Ages 40 and older · All sexes · Updated Sep 21, 2026 · NCT07652658A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonary Fibrosis
RecruitingPhase 2
Ages 40 and older · All sexes · Updated Sep 17, 2026 · NCT07516951Pulmonary Fibrosis Foundation Community Registry
RecruitingObservational studyHealthy volunteers welcome
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT05382572RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Sep 15, 2026 · NCT07002034Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets
RecruitingPhase 3
Ages 40 and older · All sexes · Updated Sep 14, 2026 · NCT07671911A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis
RecruitingPhase 2
Ages 40 and older · All sexes · Updated Sep 4, 2026 · NCT06968845Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis
RecruitingPhase 2
Ages 40 and older · All sexes · Updated Sep 3, 2026 · NCT07230288Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF)
RecruitingPhase 3
Ages 40 and older · All sexes · Updated Sep 3, 2026 · NCT07284602Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)
RecruitingPhase 2
Ages 40 and older · All sexes · Updated Sep 2, 2026 · NCT05571059Genomic and Proteomic Analysis of Disease Progression in Idiopathic Pulmonary Fibrosis (IPF)
RecruitingObservational study
Ages 18 and older · All sexes · Updated Aug 27, 2026 · NCT00373841Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry
RecruitingObservational study
Ages 21 and older · All sexes · Updated Aug 12, 2026 · NCT01915511Molecular Imaging Probes to Inform Heterogeneity in Idiopathic Pulmonary Fibrosis
RecruitingPhase 1
Ages 40 to 85 · All sexes · Updated Aug 12, 2026 · NCT04362644Dose-Escalation Study of Artesunate Patients With IPF
RecruitingPhase 1
Ages 40 and older · All sexes · Updated Aug 11, 2026 · NCT05988463WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
RecruitingPhase 2
Ages 40 and older · All sexes · Updated Aug 10, 2026 · NCT06967805H01 in Adults With Interstitial Lung Disease (The SOLIS Study)
RecruitingPhase 2
Ages 18 to 100 · All sexes · Updated Jul 28, 2026 · NCT06325696Interstitial Lung Disease Research Unit Biobank
RecruitingObservational study
Ages 18 and older · All sexes · Updated Jul 10, 2026 · NCT05392881A Study of the Natural Progression of Interstitial Lung Disease (ILD)
RecruitingObservational studyHealthy volunteers welcome
Ages 18 and older · All sexes · Updated Jun 9, 2026 · NCT00470327Rheumatoid Arthritis Patients at Risk for Interstitial Lung Disease
RecruitingObservational study
Ages 45 to 90 · All sexes · Updated May 1, 2026 · NCT03297775Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure
RecruitingPhase 1/2
Ages 18 to 60 · All sexes · Updated Jan 13, 2026 · NCT03500731Mechanisms of Familial Pulmonary Fibrosis
RecruitingObservational study
Ages 40 to 75 · All sexes · Updated Dec 31, 2025 · NCT03437486Collection of Airway, Blood and/or Urine Specimens From Subjects for Research Studies
RecruitingObservational studyHealthy volunteers welcome
Ages 18 and older · All sexes · Updated Nov 14, 2025 · NCT01776398Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis
RecruitingPhase 2
Ages 40 and older · All sexes · Updated Nov 12, 2025 · NCT05975983Zinc and Nicotinamide Riboside for Idiopathic Pulmonary Fibrosis
RecruitingPhase 2
Ages 50 and older · All sexes · Updated Nov 10, 2025 · NCT06567717Hyperpolarized Xenon-129 MRI in Idiopathic Pulmonary Fibrosis
RecruitingEarly phase 1
Ages 18 and older · All sexes · Updated Jul 9, 2025 · NCT06853145From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.